Thermo Fisher Scientific Life Sciences Solutions — Operating Income (Loss) increased by 14.6% to $968.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 14.6%, from $845.00M to $968.00M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates improved profitability and operational efficiency, while a decrease signals margin compression or rising costs.
The profit generated by the Life Sciences Solutions segment after deducting all operating expenses, including COGS, SG&A...
The primary metric for evaluating the performance of any business segment.
tmo_segment_life_sciences_solutions_operating_income_loss| Q2 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $1.72B | $2.18B | $1.33B | $855.00M | $855.00M | $855.00M | $855.00M | $845.00M | $968.00M |
| QoQ Change | — | +26.7% | -39.0% | -35.6% | +0.0% | +0.0% | +0.0% | -1.2% | +14.6% |
| YoY Change | — | — | -22.8% | -60.7% | -35.6% | — | — | -1.2% | +14.6% |
We use cookies for analytics. See our Privacy and Cookie Policy.